GBS vs. GA: Treating Both Acute & Chronic Diseases with C1q Inhibition

Time: 12:10 pm
day: Conference Day One

Details:

  • Discussing the efficacy of ANX005 in treating Guillain-Barre Syndrome
  • Optimizing dosage for acute and chronic indications
  • Summarizing the differences in the challenges of complement inhibition in acute and chronic indications

Speakers: